Artisan Partners Limited Partnership Buys 242,242 Shares of Insmed Incorporated (NASDAQ:INSM)

Artisan Partners Limited Partnership lifted its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 8.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,126,339 shares of the biopharmaceutical company's stock after buying an additional 242,242 shares during the quarter. Artisan Partners Limited Partnership owned approximately 1.75% of Insmed worth $215,842,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of INSM. Vanguard Group Inc. lifted its holdings in shares of Insmed by 6.3% during the fourth quarter. Vanguard Group Inc. now owns 18,218,973 shares of the biopharmaceutical company's stock valued at $1,257,838,000 after purchasing an additional 1,075,796 shares during the last quarter. Vestal Point Capital LP increased its position in Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock valued at $116,800,000 after buying an additional 850,000 shares in the last quarter. Eventide Asset Management LLC grew its stake in shares of Insmed by 34.2% in the third quarter. Eventide Asset Management LLC now owns 906,395 shares of the biopharmaceutical company's stock worth $66,167,000 after acquiring an additional 231,210 shares during the last quarter. Principal Financial Group Inc. grew its stake in shares of Insmed by 12.9% in the third quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock worth $136,648,000 after acquiring an additional 214,130 shares during the last quarter. Finally, TimesSquare Capital Management LLC increased its holdings in shares of Insmed by 41.4% during the fourth quarter. TimesSquare Capital Management LLC now owns 684,384 shares of the biopharmaceutical company's stock valued at $47,250,000 after acquiring an additional 200,515 shares in the last quarter.

Remove Ads

Analysts Set New Price Targets

Several analysts recently commented on INSM shares. Guggenheim reissued a "buy" rating and set a $101.00 price objective on shares of Insmed in a research report on Tuesday, February 25th. Bank of America raised their price target on shares of Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a research report on Thursday, March 20th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Insmed in a research report on Wednesday, March 19th. Truist Financial increased their target price on Insmed from $105.00 to $108.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company boosted their price target on Insmed from $85.00 to $107.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $94.00.

Insider Buying and Selling at Insmed

In other Insmed news, CEO William Lewis sold 2,978 shares of Insmed stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.36, for a total transaction of $188,686.08. Following the completion of the transaction, the chief executive officer now directly owns 392,589 shares of the company's stock, valued at $24,874,439.04. The trade was a 0.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Martina M.D. Flammer sold 3,344 shares of Insmed stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the transaction, the insider now directly owns 102,766 shares of the company's stock, valued at approximately $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 550,957 shares of company stock worth $42,992,528 over the last 90 days. 4.60% of the stock is owned by insiders.

Insmed Stock Performance

NASDAQ INSM traded down $1.90 on Monday, reaching $76.09. 657,695 shares of the stock were exchanged, compared to its average volume of 1,800,026. The firm has a market capitalization of $13.77 billion, a PE ratio of -13.63 and a beta of 1.28. Insmed Incorporated has a one year low of $21.92 and a one year high of $84.91. The company's 50-day simple moving average is $78.18 and its two-hundred day simple moving average is $74.00. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The company had revenue of $104.44 million during the quarter, compared to analysts' expectations of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Analysts expect that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.